{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:08:45Z","timestamp":1761311325551,"version":"3.41.0"},"reference-count":67,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["PI12\/02559"],"award-info":[{"award-number":["PI12\/02559"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environ and Mol Mutagen"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>End\u2010stage renal disease (ESRD) patients present high levels of phosphorus and calcium products in serum, which contribute to the development of vascular calcification and cardiovascular disease, and to low iron stores and carnitine deficiency. For these reasons, ESRD patients are generally supplemented with different medicines. Some of the most common treatments include the use of Carnicor, Venofer, and Sevelamer drugs. Carnicor is used as a source of L\u2010carnitine, acting as antioxidant and neuroprotector. Venofer is used to reduce the deficit of iron. Sevelamer is used to treat hyperphosphatemia. To determine the potential harmful genotoxic effects of these drugs, a group of 214 patients included in a hemodialysis program with different intakes of Carnicor, Venofer, and Sevelamer were evaluated. The levels of basal and oxidative DNA damage, as well as chromosomal damage, were measured in all individuals using the comet and the micronucleus assays, respectively. Our results indicate that Carnicor administration was associated with low but significant increases in the frequency of basal DNA damage and micronuclei. Environ. Mol. Mutagen. 59:302\u2013311, 2018. \u00a9 2018 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/em.22170","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T06:06:40Z","timestamp":1516687600000},"page":"302-311","source":"Crossref","is-referenced-by-count":8,"title":["Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end\u2010stage renal disease patients"],"prefix":"10.1002","volume":"59","author":[{"given":"Susana","family":"Pastor","sequence":"first","affiliation":[{"name":"Grup de Mutag\u00e8nesi, Departament de Gen\u00e8tica i de Microbiologia Edifici Cn, Universitat Aut\u00f2noma de Barcelona Bellaterra Cerdanyola del Vall\u00e8s 08193 Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica, ISCIII Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Coll","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Puigvert Barcelona 08025 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Rodr\u00edguez\u2010Ribera","sequence":"additional","affiliation":[{"name":"Grup de Mutag\u00e8nesi, Departament de Gen\u00e8tica i de Microbiologia Edifici Cn, Universitat Aut\u00f2noma de Barcelona Bellaterra Cerdanyola del Vall\u00e8s 08193 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elitsa","family":"Stoyanova","sequence":"additional","affiliation":[{"name":"Grup de Mutag\u00e8nesi, Departament de Gen\u00e8tica i de Microbiologia Edifici Cn, Universitat Aut\u00f2noma de Barcelona Bellaterra Cerdanyola del Vall\u00e8s 08193 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuray F.","family":"Corredor","sequence":"additional","affiliation":[{"name":"Grup de Mutag\u00e8nesi, Departament de Gen\u00e8tica i de Microbiologia Edifici Cn, Universitat Aut\u00f2noma de Barcelona Bellaterra Cerdanyola del Vall\u00e8s 08193 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricard","family":"Marcos","sequence":"additional","affiliation":[{"name":"Grup de Mutag\u00e8nesi, Departament de Gen\u00e8tica i de Microbiologia Edifici Cn, Universitat Aut\u00f2noma de Barcelona Bellaterra Cerdanyola del Vall\u00e8s 08193 Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica, ISCIII Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1111\/j.1523-1755.2004.00648.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1681\/ASN.2005040392"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.1038\/sj.ki.5002059"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1111\/j.1440-1797.2005.00384.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1016\/S1286-4579(00)00326-9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1111\/j.1365-2362.2010.02317.x"},{"issue":"2","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ndt\/14.suppl_2.61","article-title":"European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"14","author":"Cameron JS.","year":"1999","journal-title":"Nephrol Dial Transplant"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1097\/01.ASN.0000117774.83396.E9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_8_11_1","first-page":"190A","article-title":"Frequent IV iron dosing is associated with higher infectious deaths. ASN 30th Annual Meeting, San Antonio","volume":"8","author":"Collins A","year":"1997","journal-title":"J Am Soc Nephrol"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.1016\/j.mrrev.2013.10.001"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1002\/em.21911"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1093\/mutage\/gei003"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.1136\/bmj.c4986"},{"doi-asserted-by":"publisher","key":"e_1_2_8_16_1","DOI":"10.1093\/carcin\/18.9.1757"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.1053\/j.ajkd.2006.08.015"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1007\/s10545-010-9128-0"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1249\/MSS.0b013e3181dbacab"},{"key":"e_1_2_8_20_1","first-page":"2","article-title":"Analysis of free carnitine in plasma of ESRD patients undergoing chronic dialysis: What is the best assay?","volume":"32","author":"Fornasini G","year":"2003","journal-title":"Dial Transplant"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.4061\/2011\/156326"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.5414\/CNP73420"},{"doi-asserted-by":"publisher","key":"e_1_2_8_23_1","DOI":"10.1186\/1471-2164-10-388"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.1016\/j.lfs.2005.05.103"},{"doi-asserted-by":"publisher","key":"e_1_2_8_25_1","DOI":"10.1093\/ndt\/gfl263"},{"doi-asserted-by":"publisher","key":"e_1_2_8_26_1","DOI":"10.2147\/IJNRD.S39739"},{"doi-asserted-by":"publisher","key":"e_1_2_8_27_1","DOI":"10.1007\/s00228-004-0820-6"},{"doi-asserted-by":"publisher","key":"e_1_2_8_28_1","DOI":"10.1053\/ajkd.2002.30542"},{"doi-asserted-by":"publisher","key":"e_1_2_8_29_1","DOI":"10.1093\/oxfordjournals.ndt.a027248"},{"doi-asserted-by":"publisher","key":"e_1_2_8_30_1","DOI":"10.1038\/ki.2008.130"},{"doi-asserted-by":"publisher","key":"e_1_2_8_31_1","DOI":"10.1016\/j.phrs.2014.02.007"},{"doi-asserted-by":"publisher","key":"e_1_2_8_32_1","DOI":"10.1053\/j.ajkd.2010.10.055"},{"doi-asserted-by":"publisher","key":"e_1_2_8_33_1","DOI":"10.1016\/j.mrrev.2013.12.001"},{"doi-asserted-by":"publisher","key":"e_1_2_8_34_1","DOI":"10.1093\/ndt\/16.6.1239"},{"key":"e_1_2_8_35_1","first-page":"183","article-title":"Hereditary hemochromatosis","volume":"7","author":"Crownover BK","year":"2013","journal-title":"Am Fam Physician"},{"doi-asserted-by":"publisher","key":"e_1_2_8_36_1","DOI":"10.1093\/ajcn\/81.4.787"},{"doi-asserted-by":"publisher","key":"e_1_2_8_37_1","DOI":"10.1186\/1475-2891-13-79"},{"doi-asserted-by":"publisher","key":"e_1_2_8_38_1","DOI":"10.1093\/ndt\/gfg074"},{"doi-asserted-by":"publisher","key":"e_1_2_8_39_1","DOI":"10.1038\/ki.2013.110"},{"doi-asserted-by":"publisher","key":"e_1_2_8_40_1","DOI":"10.1016\/j.mrgentox.2016.03.002"},{"key":"e_1_2_8_41_1","first-page":"484","article-title":"Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients","volume":"23","author":"Naini AE","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"unstructured":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI).2015Clinical Practice Guidelines Hemodialysishttps:\/\/www.kidney.org\/professionals\/guidelines\/hemodialysis2015.","key":"e_1_2_8_42_1"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/sj.ki.5001994","article-title":"Pleiotropic effects of the non\u2010calcium phosphate binder sevelamer","volume":"70","author":"Nikolov IG","year":"2006","journal-title":"Kidney Int"},{"doi-asserted-by":"publisher","key":"e_1_2_8_44_1","DOI":"10.2174\/157339908784220732"},{"doi-asserted-by":"publisher","key":"e_1_2_8_45_1","DOI":"10.1053\/j.ajkd.2005.12.039"},{"doi-asserted-by":"publisher","key":"e_1_2_8_46_1","DOI":"10.1016\/j.gene.2013.10.017"},{"doi-asserted-by":"publisher","key":"e_1_2_8_47_1","DOI":"10.1002\/em.21849"},{"doi-asserted-by":"publisher","key":"e_1_2_8_48_1","DOI":"10.1186\/1475-2891-12-102"},{"doi-asserted-by":"publisher","key":"e_1_2_8_49_1","DOI":"10.4238\/vol7-2gmr441"},{"doi-asserted-by":"publisher","key":"e_1_2_8_50_1","DOI":"10.1079\/BJN20051674"},{"doi-asserted-by":"publisher","key":"e_1_2_8_51_1","DOI":"10.1093\/mutage\/geq047"},{"doi-asserted-by":"publisher","key":"e_1_2_8_52_1","DOI":"10.1002\/em.21694"},{"key":"e_1_2_8_53_1","doi-asserted-by":"crossref","first-page":"3592042","DOI":"10.1155\/2016\/3592042","article-title":"DNA damage in chronic kidney disease: Evaluation of clinical biomarkers","volume":"2016","author":"Schupp N","year":"2015","journal-title":"Oxid Med Cell Longev"},{"doi-asserted-by":"publisher","key":"e_1_2_8_54_1","DOI":"10.1097\/01.ASN.0000087087.61306.4A"},{"doi-asserted-by":"publisher","key":"e_1_2_8_55_1","DOI":"10.1111\/j.1440-1797.2012.01572.x"},{"key":"e_1_2_8_56_1","first-page":"253","article-title":"Chronic kidney disease and cancer: A troubling connection","volume":"23","author":"Stengel B.","year":"2010","journal-title":"J Nephrol"},{"doi-asserted-by":"publisher","key":"e_1_2_8_57_1","DOI":"10.1046\/j.1523-1755.2002.00637.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_58_1","DOI":"10.1053\/ajkd.2001.26094"},{"doi-asserted-by":"publisher","key":"e_1_2_8_59_1","DOI":"10.1093\/ndt\/gfp575"},{"doi-asserted-by":"publisher","key":"e_1_2_8_60_1","DOI":"10.1002\/cbf.2989"},{"doi-asserted-by":"publisher","key":"e_1_2_8_61_1","DOI":"10.1093\/carcin\/12.1.111"},{"doi-asserted-by":"publisher","key":"e_1_2_8_62_1","DOI":"10.1007\/s10534-015-9822-3"},{"key":"e_1_2_8_63_1","first-page":"4","article-title":"Toxic effects of IV iron preparations in CKD patients","volume":"28","author":"Vaziri ND.","year":"2014","journal-title":"Nephrol News Issues"},{"key":"e_1_2_8_64_1","first-page":"S1","article-title":"Causes and consequences of chronic kidney disease: Implications for managed health care","volume":"13","author":"Weiner DE.","year":"2007","journal-title":"J Manag Care Pharm"},{"doi-asserted-by":"publisher","key":"e_1_2_8_65_1","DOI":"10.5414\/CNP66433"},{"doi-asserted-by":"publisher","key":"e_1_2_8_66_1","DOI":"10.1161\/01.HYP.0000052945.84627.8F"},{"doi-asserted-by":"publisher","key":"e_1_2_8_67_1","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_68_1","DOI":"10.1007\/s00394-012-0470-x"}],"container-title":["Environmental and Molecular Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fem.22170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/em.22170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:41:53Z","timestamp":1751240513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/em.22170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/em.22170"],"URL":"https:\/\/doi.org\/10.1002\/em.22170","archive":["Portico"],"relation":{},"ISSN":["0893-6692","1098-2280"],"issn-type":[{"type":"print","value":"0893-6692"},{"type":"electronic","value":"1098-2280"}],"subject":[],"published":{"date-parts":[[2018,1,23]]}}}